New perspectives for reassessing fosfomycin: applicability in current clinical practice. (Q64945950)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

review article

3 references

11 September 2020

26 September 2020

New perspectives for reassessing fosfomycin: applicability in current clinical practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

1 reference

11 September 2020

bacterial infectious disease

2 references

11 September 2020

26 September 2020

Francisco Javier Candel

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

author name string

M Matesanz David

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

J Barberán

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

publication date

1 May 2019

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

11 September 2020

26 September 2020

Revista Española de Quimioterapia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

volume

32 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

page(s)

1-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 4.0 International

28 April 2020

copyright license

2 references

11 September 2020

Fosfomycin kinetics after intravenous and oral administration to human volunteers

26 September 2020

cites work

1 reference

12 December 2020

Biofilm testing of Staphylococcus epidermidis clinical isolates: low performance of vancomycin in relation to other antibiotics

1 reference

12 December 2020

Fosfomycin for the initial treatment of acute haematogenous osteomyelitis

1 reference

12 December 2020

Biological costs and mechanisms of fosfomycin resistance in Escherichia coli

1 reference

12 December 2020

Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms

1 reference

12 December 2020

Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections

1 reference

12 December 2020

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.

1 reference

12 December 2020

International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

1 reference

12 December 2020

Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin

1 reference

12 December 2020

High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis

1 reference

12 December 2020

Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms

1 reference

12 December 2020

Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria

1 reference

12 December 2020

Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria

1 reference

12 December 2020

Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study

1 reference

12 December 2020

Efficacy and Safety of Fosfomycin Plus Imipenem as Rescue Therapy for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant Staphylococcus aureus: A Multicenter Clinical Trial

1 reference

12 December 2020

Is high-dose intravenous fosfomycin safe for the treatment of patients prone to heart failure?

1 reference

12 December 2020

Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).

1 reference

12 December 2020

Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.

1 reference

12 December 2020

Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC).

1 reference

12 December 2020

Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC

1 reference

12 December 2020

Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model

1 reference

12 December 2020

Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance

1 reference

12 December 2020

In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.

1 reference

12 December 2020

Monitoring of high-dose fosfomycin guided by NT-proBNP.

1 reference

12 December 2020

1 reference

12 December 2020

Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens.

1 reference

12 December 2020

Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation

1 reference

12 December 2020

The management of multidrug-resistant Enterobacteriaceae

1 reference

12 December 2020

Intravenous fosfomycin - Back to the future. Systematic review and meta-analysis of the clinical literature

1 reference

12 December 2020

Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC).

1 reference

12 December 2020

In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

1 reference

12 December 2020

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

1 reference

12 December 2020

Emergence of Plasmid-Mediated Fosfomycin-Resistance Genes among Escherichia coli Isolates, France

1 reference

12 December 2020

Antimicrobial susceptibility of microorganisms that cause urinary tract infections in pediatric patients.

1 reference

12 December 2020

Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.

1 reference

12 December 2020

Fosfomycin: Pharmacological, Clinical and Future Perspectives.

1 reference

12 December 2020

Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coli.

1 reference

12 December 2020

Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infection diseases specialists practicing in large hospitals

1 reference

12 December 2020

Clinical efficacy of fosfomycin combinations against a variety of gram-positive cocci

1 reference

12 December 2020

Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences

1 reference

12 December 2020

Multidrug-resistant Gram-negative infection in solid organ transplant recipients: implications for outcome and treatment

1 reference

12 December 2020

Current approach to fosfomycin: From bench to bedside

1 reference

12 December 2020

Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31131586 AND SRC:MED&resulttype=core&format=json

28 April 2020

PubMed publication ID

31131586

1 reference